356 related articles for article (PubMed ID: 28738160)
1. Atrial-selective K
Ravens U
Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
[TBL] [Abstract][Full Text] [Related]
2. Atrial fibrillation: Therapeutic potential of atrial K
Ravens U; Odening KE
Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
[TBL] [Abstract][Full Text] [Related]
3. Atria-selective antiarrhythmic drugs in need of alliance partners.
Peyronnet R; Ravens U
Pharmacol Res; 2019 Jul; 145():104262. PubMed ID: 31059791
[TBL] [Abstract][Full Text] [Related]
4. Atrial-Selective Potassium Channel Blockers.
Voigt N; Dobrev D
Card Electrophysiol Clin; 2016 Jun; 8(2):411-21. PubMed ID: 27261831
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of cardiac potassium channels.
Li GR; Dong MQ
Adv Pharmacol; 2010; 59():93-134. PubMed ID: 20933200
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.
Voigt N; Rozmaritsa N; Trausch A; Zimniak T; Christ T; Wettwer E; Matschke K; Dobrev D; Ravens U
Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):251-9. PubMed ID: 19760273
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
[TBL] [Abstract][Full Text] [Related]
9. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
McEwen DP; Martens JR
Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic Mechanisms of SK Channel Inhibition in the Rat Atrium.
Skibsbye L; Wang X; Axelsen LN; Bomholtz SH; Nielsen MS; Grunnet M; Bentzen BH; Jespersen T
J Cardiovasc Pharmacol; 2015 Aug; 66(2):165-76. PubMed ID: 25856531
[TBL] [Abstract][Full Text] [Related]
11. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
[TBL] [Abstract][Full Text] [Related]
12. Effects of a highly selective acetylcholine-activated K+ channel blocker on experimental atrial fibrillation.
Machida T; Hashimoto N; Kuwahara I; Ogino Y; Matsuura J; Yamamoto W; Itano Y; Zamma A; Matsumoto R; Kamon J; Kobayashi T; Ishiwata N; Yamashita T; Ogura T; Nakaya H
Circ Arrhythm Electrophysiol; 2011 Feb; 4(1):94-102. PubMed ID: 21156770
[TBL] [Abstract][Full Text] [Related]
13. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
[TBL] [Abstract][Full Text] [Related]
14. Rate-Dependent Role of I
Aguilar M; Feng J; Vigmond E; Comtois P; Nattel S
Biophys J; 2017 May; 112(9):1997-2010. PubMed ID: 28494969
[TBL] [Abstract][Full Text] [Related]
15. Targeting cardiac potassium channels for state-of-the-art drug discovery.
Walsh KB
Expert Opin Drug Discov; 2015 Feb; 10(2):157-69. PubMed ID: 25400064
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of the muscarinic potassium current by KB130015, a new antiarrhythmic agent to treat atrial fibrillation].
Borchard R; van Bracht M; Wickenbrock I; Prull MW; Pott L; Trappe HJ
Med Klin (Munich); 2005 Nov; 100(11):697-703. PubMed ID: 16328176
[TBL] [Abstract][Full Text] [Related]
17. Atrial selectivity of antiarrhythmic drugs.
Ravens U; Poulet C; Wettwer E; Knaut M
J Physiol; 2013 Sep; 591(17):4087-97. PubMed ID: 23732646
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of I
Juhász V; Hornyik T; Benák A; Nagy N; Husti Z; Pap R; Sághy L; Virág L; Varró A; Baczkó I
Can J Physiol Pharmacol; 2018 Jan; 96(1):18-25. PubMed ID: 28892643
[TBL] [Abstract][Full Text] [Related]
19. Revealing kinetics and state-dependent binding properties of I
Ellinwood N; Dobrev D; Morotti S; Grandi E
Chaos; 2017 Sep; 27(9):093918. PubMed ID: 28964116
[TBL] [Abstract][Full Text] [Related]
20. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
